Although expression of cutaneous lymphocyte-associated antigen (CLA) is thought to be a specific marker of skin "homing" T cells, it has become clear that CLA is a good marker for high levels of fucosyltransferase VII (Fuc-TVII) activity but does not necessarily represent the epitope required for binding to E-selectin (Wagers et al, 1996 (Wagers et al, , 1997 . Therefore, expression of Fuc-TVII is an attractive candidate for identifying skin "homing" T cells. However, analyses of Fuc-TVII expression in human T cells have been performed only at the mRNA level (Nakayama et al, 2000) because of the lack of mAb. In this study Fuc-TVII was for the first time visualized in individual cells by using a novel mAb that we developed. Double immunofluorescence and immunohistochemistry demonstrated the coexpression of Fuc-TVII and CLA in cell lines in which Fuc-TVII mRNA was shown to be expressed at high levels: whereas CLA expression was seen in the cell membrane, Fuc-TVII was identified in a supra-or perinuclear location. Cytoplasmic Fuc-TVII expression was also detectable in both CD4 ϩ and CD8 ϩ T cells purified from peripheral blood. Fuc-TVII was also expressed at high levels in many CLA ϩ T cells infiltrating the skin. In these peripheral T cells, unlike in cell lines, cytoplasmic expression of Fuc-TVII was not always associated with surface CLA expression. This mAb would serve as a valuable tool for selectively identifying a novel subset of skin "homing" T cells that are not detected by the conventional method because of the lack of CLA expression. (Lab Invest 2001, 81:771-773).
F
rom BALB/c mice immunized with recombinant human fucosyltransferase VII (Fuc-TVII), eight hybridomas were identified as those secreted antibodies specifically recognizing a 44-kd Fuc-TVII protein in immunoblotting. Immunohistochemistry was performed on several cell lines and peripheral blood T cells, both of which were centrifuged onto microscope slides and tissue specimens, as described previously (Teraki et al, 1994) . The slides fixed with 4% paraformaldehyde (PFA) were incubated with 5% normal swine serum (NSS; Dakopatts, Glostrup, Denmark) diluted with 0.5% sodium azide in PBS for 30 minutes. They were then incubated at 4°C for 16 hours with Fuc-TVII-specific mAb in permeabilization buffer (0.5% saponin and 5% NSS in PBS), and were treated with 3% H 2 O 2 for 10 minutes. For efficient intracellular staining of Fuc-TVII, a 70°C temperature treatment for 5 minutes was required before staining. Although we attempted a variety of antigen retrieval methods, a combination of heating and permeabilization by saponin was found to stain Fuc-TVII most prominently. The activity of the primary antibody was revealed by incubating with biotinylated horse anti-mouse immunoglobulin G (IgG) (Vector Laboratories, Burlingame, California) and streptavidin/biotinylated horseradish peroxidase complex (Dakopatts), followed by the visualization of peroxidase activity using 3-amino-9-ethylcarbazol (AEC, Dakopatts). Immunoreactivity to Fuc-TVII was detected readily in the cytoplasm of the Fuc-TVII-transfected Namalwa cells, whereas no reactivity was noted in the negative controls, such as Namalwa cells. The staining for Fuc-TVII was found in a supranuclear location, consistent with the Golgi staining pattern. Of the eight mAbs tested, KM1939 gave the most intense staining. To investigate whether Fuc-TVII expression was selectively associated with that of cutaneous lymphocyte-associated antigen (CLA), we initially used double confocal microscopy. The first staining was performed with Fuc-TVII that was visualized by Cy 3-donkey anti-mouse IgG (Jackson ImmunoResearch, West Grove, Pennsylvania), and the second staining with FITC-labeled HECA-452, a mAb for CLA (a kind gift from L. Picker, Department of Pathology, University of Texas Southwestern Medical Center, Dallas, Texas). This experiment confirmed the coexpression of CLA and Fuc-TVII in the same cell, but in a distinct localization (Fig. 1) .
We next examined whether Fuc-TVII expression was restricted to a limited T cell subpopulation ex-pressing CLA in peripheral blood. For efficient double immunohistochemical staining for Fuc-TVII and CLA in these T cells, the first staining step (Fuc-TVII) with the above protocol was used, and this was followed by the second step (CLA), in which avidin-biotin-alkaline phosphatase complex (ABC-AP) and Vector blue detection system (Vector Laboratories) were used. A substantial proportion of CLA ϩ peripheral blood mononuclear cells (PBMC) were positive for Fuc-TVII in a supranuclear or perinuclear location ( Fig. 2A) . Representative double staining patterns of purified CD4 ϩ and CD8 ϩ T cells are shown in Figure 2, To ascertain whether this mAb was suitable for in situ detection of Fuc-TVII in infiltrating T cells, skin biopsy specimens obtained from patients with lichen planus, psoriasis vulgaris, and erythema multiforme were assessed by immunohistochemistry. The sections were stained with the above protocol. Double immunohistochemical staining showed that Fuc-TVII was detected in the cytoplasm of CLA-expressing T cells (Fig. 3) . Our success would help to open the way for future experiments to identify a novel population of skin "homing" T cells at the single cell level, both in vitro and in situ, which was impossible by the conventional anti-CLA mAb.
Figure 1.
Confocal microscopic images of the fucosyltransferase VII (Fuc-TVII)-transfected Namalwa cells dually immunostained for cutaneous lymphocyteassociated antigen (CLA, green) and Fuc-TVII (red) and visualized using a laser confocal system equipped with an argon/krypton laser (original magnification, ϫ960). CLA expression was seen in the cell membrane, whereas the Fuc-TVII was detected as either diffuse immune reactants or punctate reactants.
Figure 2.
Double immunohistochemical detection of Fuc-TVII and CLA in peripheral blood mononuclear cells (PBMC) (A) and purified CD4 ϩ (B) and CD8 ϩ (C) T cells (original magnification, ϫ132). PBMC were obtained from healthy blood donors. Purified CD4 ϩ and CD8 ϩ T cells were further isolated from the PBMC preparations by negative selection using a human CD4 ϩ or CD8 
